Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance

 
• By Joseph Haas, Ian Haydock, Anju Ghangurde, and Vibha Ravi
  
DealWatch_1200x675
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business